http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Pietro Andreone ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Giovanni Vitale,Giulia Simonetti,Martina Pirillo,Gianfranco Taruschio,Pietro Andreone 대한신경정신의학회 2016 PSYCHIATRY INVESTIGATION Vol.13 No.5
Bile Salt Export Pump (BSEP) Deficiency disease, including Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2), is a rare disease, usually leading within the first ten years to portal hypertension, liver failure, hepatocellular carcinoma. Often liver transplantation is needed. Sodium 4-phenylbutyrate (4-PB) seems to be a potential therapeutic compound for PFIC2. Psychiatric side effects in the adolescent population are little known and little studied since the drug used to treat children and infants. So we described a case of Caucasian boy, suffering from a late onset PFIC2, listed for a liver transplant when he was sixteen and treated with 4-FB (200 mg per kilogram of body weight per day). The drug was discontinued for the onset of bipolar and related disorders. This case illustrates possible psychiatric side effects of the drug.
-
( Yoon Jun Kim ),( Young-suk Lim ),( Shalimar ),( Xiaoli Ma ),( Akash Shukla ),( Huy N. Trinh ),( Pietro Andreone ),( Jae-seok Hwang ),( Vithika Suri ),( George Wu ),( Ondrej Podlaha ),( Anuj Gaggar ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: HBeAg seroconversion remains an important endpoint for antiviral therapy. We previously reported on HBeAg loss following 48 weeks of oral antiviral therapy in the ongoing phase 3 study described below. Here we present an updated evaluation of factors associated with HBeAg loss with/without anti-HBe seroconversion following 3 years of antiviral therapy. Methods: The study included adults with HBeAg-positive CHB enrolled in a Phase 3 trial(Study GS-US-320-0110) comparing TAF 25mg QD vs. TDF 300mg QD. At Week144, 340(39%; TAF 226; TDF 114) patients had received 1year of open label TAF 25mg QD after switching from double blind(DB) treatment. The associations between HBeAg loss at Week144 with host, viral, and treatment-related factors, including on-treatment virologic suppression, were determined using logistic regression analy ses. Results: Among 873 ipatients, the median age was 36yrs, 82% were Asian, and median baseline (BL) ALT and HBV DNA were 85U/L (IQR 60-138) and 7.9 log10IU/mL (IQR 6.9- 8.6), respectively. At Week144, a total of 194patients (22%) experienced HBeAg loss and 142 patients (16%) underwent HBeAg seroconversion (Figure 1). Compared with subjects with persistent HBeAg-positivity, those with HBeAg loss were older (median age, 35 vs. 40yrs), were infected with non-genotype D HBV (75% vs 86%), had lower median HBsAg levels (4.3 vs 3.8 log10 IU/mL), a higher median BL ALT (83 vs. 101U/L), a higher prevalence of presumed cirrhosis (Fibro Test ≥0.75:6.4% vs. 13.2%), and lower median BL serum HBV DNA (8.1 vs. 7.7 log10 IU/mL) (all P≤0.005). In multivariate analysis, baseline HBV DNA<8 log10 was an independent predictor of both HBeAg loss(OR: 1.816 [1.174-2.808]; P=0.007) and seroconver sion (OR: 2.512 [1.684-3.746]; P<0.001); treatment with TAF in the DB period was a predictor of seroconversion (OR:1.596 [1.044-2.439]; P=0.031) but not loss. Conclusions: Following 144 weeks of treatment, HBeAg loss/ seroconversion rates remains low in subjects treated with TAF or TDF with lower baseline HBV DNA levels associated with higher rates of response.
KCI
스콜라연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
